Randall J. Bateman, MD, a leading Alzheimer’s disease researcher and longtime partner of GHR in our Alzheimer’s Prevention efforts, has been elected to the National Academy of Medicine – a part of the National Academy of Sciences, to which membership is considered one of the highest honors in the fields of health and medicine in the United States.
Dr. Bateman was selected for his groundbreaking work in discovering and developing diagnostic tools for Alzheimer’s disease. GHR has been privileged to partner with Dr. Bateman on the development of a blood test for early Alzheimer’s detection, as well as on the Dominantly Inherited Alzheimer Network (DIAN), an international research partnership focused on understanding rare forms of Alzheimer’s disease caused by gene mutations. Dr. Bateman also created the Dominantly Inherited Alzheimer’s Network-Trials Unit (DIAN-TU) platform, the first clinical trial to test whether drug treatments prior to dementia can prevent Alzheimer’s.
GHR Foundation is partnering boldly with a consortium of government, industry, academic research and other philanthropists on a game-changing undertaking – the prevention of Alzheimer’s disease. Learn more here.
Dr. Bateman was selected for his groundbreaking work in discovering and developing diagnostic tools for Alzheimer’s disease. GHR has been privileged to partner with Dr. Bateman on the development of a blood test for early Alzheimer’s detection, as well as on the Dominantly Inherited Alzheimer Network (DIAN), an international research partnership focused on understanding rare forms of Alzheimer’s disease caused by gene mutations. Dr. Bateman also created the Dominantly Inherited Alzheimer’s Network-Trials Unit (DIAN-TU) platform, the first clinical trial to test whether drug treatments prior to dementia can prevent Alzheimer’s.
GHR Foundation is partnering boldly with a consortium of government, industry, academic research and other philanthropists on a game-changing undertaking – the prevention of Alzheimer’s disease. Learn more here.